Hexarelin
Also known as: examorelin
A synthetic hexapeptide secretagogue, also studied for reported cardiac effects independent of growth hormone release.
Development status: Preclinical — laboratory and animal studies only
Identifiers and molecular characteristics
- CAS number
- Not verified
- Molecular formula
- Not verified
- Molecular mass
- Not verified
- Amino-acid sequence
- Not verified
- PubChem CID
- Not verified
Identifiers are published only with a source and a check date. Fields marked “not verified” have not yet been confirmed against a primary source — we show the gap rather than an unchecked figure. Always confirm against the certificate of analysis for the specific lot you hold.
Biological targets
- GHS-R1a
- CD36 (reported)
Mechanism of action
Ghrelin receptor agonism, with literature also describing interaction with CD36 in cardiovascular tissue — a proposed route for effects not mediated by growth hormone.
Research evidence and its limits
Preclinical pharmacology and limited early human work.
Safety considerations
No regulatory authority has assessed this compound as safe or effective for any human indication. The published record is predominantly laboratory and animal work, which does not establish human safety. Supplied and discussed here strictly as a laboratory research material. Not a medicine, not for human or veterinary administration, and nothing on this page should be read as a dosing, treatment or safety recommendation.
Analytical identification and quality testing
Identity by high-resolution mass spectrometry against the expected mass, purity by RP-HPLC with UV detection. For a sequence-defined peptide, enzymatic digestion followed by peptide mapping gives far stronger identity evidence than mass alone, because isomers and closely related sequences can share a mass.
Regulatory status
Not an approved medicine.
References
Related compounds
Entry last reviewed 2026-10-11. Regulatory status and scientific understanding change; verify against primary sources before relying on anything here.